SAMM50

Across TCGA pan-cancer cohorts, SAMM50 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SAMM50 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SAMM50 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SAMM50 expression acts as an unfavorable survival marker.

OV, PAAD, and PRAD are the cancer types where SAMM50 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.280	0.541	.038	18	view →
PAAD	OS	Median	All	0.112	0.640	.004	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SAMM50–OV (DFS)

Open the OV breakdown →